Home＞BUSINESS
Daiichi Sankyo to Shed Non-Cancer R&D Costs, Allocate More Resources to Oncology: CEO(Dec.14.2017)
Daiichi Sankyo CEO Joji Nakayama |
Daiichi Sankyo is re-allocating its R&D investments as the company works to expedite the development of its key oncology candidates including HER2-targeting antibody drug conjugate (ADC) DS-8201, Chairman and CEO Joji Nakayama revealed ...
(LOG IN FOR FULL STORY)
-
- Prescribers Asked to Stop New Enbrel Biosimilar Use as Maker Can’t Keep Up with Demand Oct.19
- Takeda Earns Japan Clearance for Shire Acquisition Oct.19
- Asahi Kasei Obtains Patent License for iPS Cell-Derived Cartilage Regeneration Technology Oct.18
- Sumitomo Dainippon to Invest in, Conduct Joint R&D with Cyborg Tech Startup Oct.18
- Nippon Shinyaku Seeks Japan Approval for Hepatic VOD Treatment Defibrotide Oct.18
- MHLW Proposes New Approval Framework Incorporating Conditional OK, Sakigake Scheme(Oct.19)
- Prescribers Asked to Stop New Enbrel Biosimilar Use as Maker Can’t Keep Up with Demand(Oct.19)
- Council Approves MHLW’s Plan to Deal with Difficult-to-Develop Drugs and Indications(Oct.19)
- PMDA to Focus on Proper Use of Sakigake and Conditional Approval Systems in Its 4th Midterm Plan(Oct.19)
- Takeda Earns Japan Clearance for Shire Acquisition(Oct.19)
